Management of infusion-related reactions in cancer therapy: strategies and challenges

Barroso, A.; Estevinho, F.; Hespanhol, V.; Teixeira, E.; Ramalho-Carvalho, J.; Araújo, A.

doi:10.1016/j.esmoop.2024.102922

ESMO Open

2024

DOI: 10.1016/j.esmoop.2024.102922

|View full text |Cite

Management of infusion-related reactions in cancer therapy: strategies and challenges

A. Barroso,

F. Estevinho,

V. Hespanhol

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Revolutionizing cancer treatment: the rise of personalized immunotherapies

Fayyaz,

Haqqi,

Khan

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Interest in biological therapy for cancer has surged due to its precise targeting of cancer cells and minimized impact on surrounding healthy tissues. This review discusses various biological cancer therapies, highlighting advanced alternatives over conventional chemotherapy alone. It explores DNA and RNA-based vaccines, T-cell modifications, adoptive cell transfer, CAR T cell therapy, angiogenesis inhibitors, and the combination of immunotherapy with chemotherapy, offering a holistic view of the potential in cancer treatment. Additionally, it discusses the role of nanotechnology in increasing the efficacy of cancer-targeting drugs, as well as cytokine and immunoconjugate therapies for bolstering immune system effectiveness against neoplastic cells. The potential of gene potential for precise targeting of cancer-linked genes and the application of oncolytic viruses against virus-associated cancers are also discussed. The review identifies significant advancements in the targeted treatment of cancer by biological methods. It acknowledges the challenges, including drug resistance and the need for high specificity in certain therapies, while also highlighting the effectiveness of cancer vaccines, modified T-cells, and oncolytic viruses. Biological therapies are a promising frontier in cancer treatment, offering the potential for more personalized and effective therapeutic strategies. Despite existing challenges, ongoing research and clinical trials are fundamental for overcoming current limitations and enhancing the efficacy of biological therapies in cancer care.

show abstract

Revolutionizing cancer treatment: the rise of personalized immunotherapies

Fayyaz,

Haqqi,

Khan

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis

Belloni,

Tiberio,

De Sanctis

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association

Park,

Kim,

Kim

et al. 2024

Dement Neurocogn Disord

View full text Add to dashboard Cite

Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Management of infusion-related reactions in cancer therapy: strategies and challenges

Cited by 6 publications

References 132 publications

Revolutionizing cancer treatment: the rise of personalized immunotherapies

Revolutionizing cancer treatment: the rise of personalized immunotherapies

Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association

Contact Info

Product

Resources

About